Genfit S.A.

Paris Stock Exchange GNFT.PA

Genfit S.A. Price to Sales Ratio (P/S) on January 14, 2025: 5.55

Genfit S.A. Price to Sales Ratio (P/S) is 5.55 on January 14, 2025, a -19.08% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Genfit S.A. 52-week high Price to Sales Ratio (P/S) is 11.57 on October 17, 2024, which is 108.65% above the current Price to Sales Ratio (P/S).
Genfit S.A. 52-week low Price to Sales Ratio (P/S) is 5.55 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
Genfit S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 7.75.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Paris Stock Exchange: GNFT.PA

Genfit S.A.

CEO	Mr. M. Pascal Prigent
IPO Date	Dec. 19, 2006
Location	France
Headquarters	Parc EurasantE
Employees	169
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Key trends

Past 5 years